Muscarinic Receptor Binding of Imidafenacin in the Human Bladder Mucosa and Detrusor and Parotid Gland
|
|
- Holly Nelson
- 6 years ago
- Views:
Transcription
1 LUTS (2011) 3, ORIGINAL ARTICLE Muscarinic Receptor Binding of Imidafenacin in the Human Bladder Mucosa and Detrusor and Parotid Gland Masanao SEKI, 1 Masaki OGODA, 1 Shiori KURAOKA, 1 Atsushi OTSUKA, 2 Seiichiro OZONO, 2 Masayuki TAKEDA, 3 Keisuke MASUYAMA, 3 Isao ARAKI, 4 and Shizuo YAMADA 1 1 Department of Pharmacokinetics and Pharmacodynamics and Global Center of Excellence (COE) Program, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan, 2 Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan, 3 Department of Urology and Otolaryngology, School of Medicine, University of Yamanashi, Chuo, Japan, and 4 Department of Urology, Shiga University of Medical Science, Ohtsu, Japan Objectives: The current study aimed to characterize comparatively the binding of imidafenacin to muscarinic receptors in the human bladder mucosa and detrusor muscle and parotid gland. Methods: The muscarinic receptor in homogenates of human tissues (bladder mucosa and detrusor muscle and parotid gland) was measured using a radioligand binding assay with [N-methyl- 3 H]scopolamine methyl chloride ([ 3 H]NMS). Results: Imidafenacin competed with [ 3 H]NMS for binding sites in the bladder mucosa and detrusor muscle and parotid gland, and its affinity was significantly ( times) higher than that of oxybutynin. Also, the affinity of imidafenacin for muscarinic receptors was approximately two-fold higher in the parotid gland than bladder tissue. The affinity of imidafenacin in the mucosa was similar to that in the detrusor muscle, suggesting that this agent exhibits therapeutic effects by blocking muscarinic receptors in the mucosa as well as detrusor muscle. Scatchard analysis revealed that imidafenacin increased significantly (approximately four-fold) K d values for [ 3 H]NMS binding in the human detrusor muscle and parotid gland, with little effect on B max values. This observation indicates that imidafenacin binds to the muscarinic receptors in human tissues in a competitive and reversible manner. Conclusion: Imidafenacin binds to muscarinic receptors in the human bladder mucosa and detrusor muscle and parotid gland with high affinity. This agent was considered to exhibit therapeutic effects on the lower urinary tract symptoms due to an overactive bladder by blocking muscarinic receptors in the urothelium as well as detrusor muscle. Key words detrusor, human bladder mucosa, imidafenacin, muscarinic receptor, parotid gland 1. INTRODUCTION Overactive bladder (OAB), characterized by frequency, urgency, urge incontinence and nocturia, affects many elderly people. 1 Antimuscarinic agents used to treat OAB decrease the contractility of the bladder during micturition by blocking muscarinic receptors in the detrusor muscle to increase the capacity of the bladder and decrease urgency during the storage phase. 2 It has been shown that the M 3 subtype mediates the direct contractile response to acetylcholine in the urinary bladder. In fact, the contractile response to muscarinic agonists exhibited an M 3 -type profile in a study of competitive antagonism 3 and these contractions were markedly decreased in the urinary bladder of M 3 receptor knockout mice. 4 The bladder urothelium not only provides a barrier to diffusion but also serves a sensory function and releases signaling molecules such as acetylcholine and adenosine 5 -triphosphate. Although the function of such innervation remains unclear, muscarinic receptors are present on the mucosa (urothelium) as well as detrusor muscle of the urinary bladder. 5 7 Therefore, mucosal muscarinic receptors may represent a novel site of action of antimuscarinic agents for the treatment of bladder disorders. In this connection, Kim et al. 8 showed that intravesically infused antimuscarinic agents suppressed carbacholinduced bladder overactivity, possibly implying a blockage of muscarinic receptors in bladder-afferent pathways. Mostofthesideeffectsofantimuscarinic treatment in patients with OAB are thought to be caused by significant binding to muscarinic receptors in organs other than the Correspondence: Shizuo Yamada, PhD, Department of Pharmacokinetics and Pharmacodynamics and Global Center of Excellence (COE) Program, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Surugaku, Shizuoka , Japan. Tel: ; Fax: yamada@u-shizuoka-ken.ac.jp Received 23 December 2010; accepted 25 January 2011 DOI: /j x
2 Imidafenacin in Human Bladder 65 bladder. The dry mouth caused by antimuscarinic agents, for example, is mainly due to a blockade of muscarinic receptors in the salivary gland. The novel antimuscarinic agent imidafenacin, 4-(2- methyl 1-H-imidazol-1-yl)-2,2,diphenyl butanamide) (KRP-197/ONO-8025), is currently being developed for the treatment of OAB in Japan. Imidafenacin is a welltolerated agent with fewer adverse effects It has been reportedtohavehighaffinityform 3 receptors, which play an important role in bladder contraction, to exhibit functional selectivity toward the bladder over the salivary gland, and to have little pharmacological effect on the central nervous system at high doses. 13,14 Murakami et al. 15 showed that imidafenacin exerted an inhibitory effect on postjunctional as well as prejunctional muscarinic receptors to modulate the release of acetylcholine in human detrusor smooth muscles. Thus, imidafenacin may select the bladder over the salivary gland, reducing the risk of side effects on the central nervous system in the treatment of OAB. Recently, we showed that imidafenacin administered orally distributes predominantly to the bladder and exerts a more selective and longerlasting effect on the bladder than other organs such as the submaxillary gland. 16 Futhermore, the imidafenacin excreted in urine may play an important role in the pharmacokinetic and pharmacological selectivity. The present study aimed to compare the binding characteristics of imidafenacin to pharmacologically relevant muscarinic receptors in the human bladder mucosa and detrusor muscle and parotid gland using a radioligand binding assay. 2. METHODS 2.1. Materials [N-Methyl- 3 H]scopolamine methyl chloride ([ 3 H]NMS; 3.03 TBq/mmol) was purchased from PerkinElmer Life Sciences, Inc. (Boston, MA, USA). Imidafenacin was donated by Kyorin Pharmaceutical Co., Ltd. (Tokyo, Japan). All other chemicals were purchased from commercial sources. Specimens of detrusor muscle and mucosa were collected from bladder carcinoma patients (n = 7) undergoing open surgery, while specimens of parotid gland were obtained from patients undergoing the surgical excision of aparotidtumor(n = 5). Informed consent was obtained from each patient prior to their operation. All specimens used in the experiments were taken from areas macroscopically free of tumors, immediately frozen, and stored at 80 C. This study was conducted according to guidelines approved by the Ethics Committees of the University of Shizuoka, University of Yamanashi, and Hamamatsu University Medical School Tissue preparation The tissues were carefully minced with scissors and homogenized with a Kinematica Polytron homogenizer in 19 volumes of ice-cold 30 mm Na + /HEPES buffer (ph 7.5). The homogenates were then centrifuged at g for 20 min. The resulting pellets were resuspended in the same buffer for the binding assay Muscarinic receptor binding assay The binding assay for muscarinic receptors was performed using [ 3 H]NMS as described previously. 17 In the saturation binding experiments, the tissue homogenate was incubated with various concentrations ( nm) of [ 3 H]NMS in 30 mm Na + /HEPES buffer (ph 7.5). In the competition binding experiments, the tissue homogenate was incubated with [ 3 H]NMS (1.0 nm) in the presence of each antimuscarinic agent. Incubation was carried out for 60 min at 25 C and the reaction was terminated by rapid filtration (Cell harvester; Brandel Co, Gaithersburg, MD, USA) through Whatman GF/B glass filters. The filters were rinsed three times with 3 ml of ice-cold 50 mm Na + /K + phosphate buffer (ph 7.4). Tissue-bound radioactivity was extracted from the filters overnight in scintillation fluid, and the radioactivity was measured with a liquid scintillation counter. Specific [ 3 H]NMS binding was determined experimentally from the difference between counts in the absence and presence of 1 μm atropine. Protein concentrations were measured by the method of Lowry et al Data analysis The [ 3 H]NMS binding data was subjected to a nonlinear regression analysis using Graph Pad PRISM (version 4, Graph Pad Software, San Diego, CA, USA). The apparent dissociation constant (K d ) and maximal number of binding sites (B max )for[ 3 H]NMS were estimated. The ability of nonlabeled agents to inhibit specific [ 3 H]NMS binding (1.0 nm) was estimated from the IC 50,whichis the molar concentration of antimuscarinic agents necessary to displace 50% of specific [ 3 H]NMS binding. The inhibition constant, K i, was calculated from the equation, K i = IC 50 /(1 + L/K d ), where L represents the concentration of [ 3 H]NMS. Statistical analyses of the data were performed with Student s t-test. The data were expressed as the mean ± standard error. Statistical significance was accepted at P < RESULTS 3.1. [ 3 H]NMS binding sites in the human bladder mucosa and detrusor muscle and parotid gland Specific binding of [ 3 H]NMS at nm in homogenates of human bladder mucosa and detrusor muscle and parotid gland was saturable and of high affinity, and the non-specific binding determined in the presence of 1 μm atropine was extremely low. The non-linear regression analysis revealed a linear plot in these tissues, suggesting a single population of high-affinity binding sites for [ 3 H]NMS. The calculated K d values for specific [ 3 H]NMS binding in the mucosa and detrusor and parotid gland were 237 ± 49, 260 ± 82 and 210 ± 20 pm, respectively, and the B max values were 85.3 ± 5.7, 69.8 ± 4.3 and 172 ± 50 fmol/mg protein, respectively (Table 1).
3 66 Masanao Seki et al. TABLE 1. K d and B max values for [N-methyl- 3 H]scopolamine methyl chloride ([ 3 H]NMS) binding in homogenates of human detrusor and parotid gland K d B max Tissue (pm) (fmol/mg protein) Detrusor 237 ± ± 5.7 Mucosa 260 ± ± 4.3 Parotid gland 210 ± ± 50 The binding of [ 3 H]NMS ( nm) in homogenates of human detrusor and parotid gland was measured. Each value represents the mean ± SEM for four to six samples Inhibition by imidafenacin of specific [ 3 H]NMS binding in the bladder mucosa and detrusor muscle and parotid gland In the competition-binding experiments, imidafenacin ( nm) competed with [ 3 H]NMS for binding sites in the bladder mucosa and detrusor muscle and parotid gland in a concentration-dependent manner (Fig. 1). Based on the K i values, the muscarinic receptor binding affinity of imidafenacin was approximately twofold higher in the parotid gland than in the detrusor and mucosa (Table 2). A similar concentration-dependent inhibition of specific [ 3 H]NMS binding in these tissues was observed for oxybutynin (3 300 nm) (Fig. 1). Thus, the affinity for muscarinic receptor of imidafenacin was 5.6 (detrusor), 2.6 (mucosa) and 8.7 (parotid gland)-fold higher than that of oxybutynin as shown by the ratios of K i values and the difference was statistically significant (Table 2). The Hill coefficients for both agents in these tissues were close to unity Effect of imidafenacin on [ 3 H]NMS binding parameters in the detrusor muscle and parotid gland The muscarinic receptor binding of imidafenacin was further characterized by measuring the binding parameters of [ 3 H]NMS in the detrusor muscle and parotid gland in the presence of this agent at concentrations around the IC 50 (5 or 10 nm). Imidafenacin increased significantly (4.1-fold) the K d values for specific [ 3 H]NMS binding in the detrusor muscle and parotid gland (Table 3). On the other hand, the B max values were little affected in the presence of imidafenacin. Similarly, oxybutynin (30 nm) significantly (8.9- and 3.2-fold, respectively) enhanced the K d values for [ 3 H]NMS binding in the detrusor muscle and parotid gland with little effect on the B max values (Table 3). 4. DISCUSSION Muscarinic receptor binding sites of imidafenacin in the human bladder mucosa (urothelium) and detrusor muscle and parotid gland were characterized using a radioligand binding assay with [ 3 H]NMS. [ 3 H]NMS exhibited high-affinity binding to homogenates of the mucosa and detrusor muscle, which was specific and saturable. Both K d and B max values for the specific binding of [ 3 H]NMS in the mucosa were comparable to those for detrusor Fig. 1 Competitive inhibition by imidafenacin and oxybutynin of specific [N-methyl- 3 H]scopolamine methyl chloride ([ 3 H]NMS) binding in homogenates of human detrusor ( ), mucosa ( ) and parotid gland ( ). Theordinateis[ 3 H]NMS binding (% of control) and the abscissa is logarithmic molar concentrations of imidafenacin ( nm) and oxybutynin (3 300 nm). Each point represents the mean ± SEM for three to seven samples. muscle, suggesting the existence of muscarinic receptors in the human urothelium with a similar affinity and density to those in the detrusor muscle. Imidafenacin competed with [ 3 H]NMS for binding sites in the human bladder mucosa and detrusor muscle and parotid gland, and its affinity was significantly ( times) higher than that of oxybutynin. Also, the affinity of imidafenacin for muscarinic receptors was significantly higher in the parotid gland than bladder tissue. A similarly high affinity of imidafenacin for muscarinic receptors in the exocrine gland was also observed in rats. 16 The affinity of this agent in the human mucosa was similar to that in the detrusor muscle, suggesting that imidafenacin exhibits therapeutic effects by blocking muscarinic receptors in the mucosa as well as in the detrusor muscle. Further, since imidafenacin is reportedly excreted in human urine at concentrations that exert pharmacological effects on the bladder, 19 the mucosal muscarinic receptors could be blocked by this agent excreted in urine directly from the bladder s luminal side as well as the circulating blood. In fact, our recent study showed that imidafenacin instilled intravesically at pharmacological doses bound significantly to muscarinic receptors in the rat bladder. 16 Scatchard analysis revealed that imidafenacin increased significantly K d values for [ 3 H]NMS binding in the human detrusor muscle and parotid gland, with little effect on B max values. This observation may indicate that imidafenacin binds to the muscarinic receptors in human tissues in a competitive and reversible manner. The salivary gland contains predominantly M 3 muscarinic receptors, 20,21 whereas the bladder contains both the M 2 and M 3 subtypes, though M 2 receptors dominate. 22 Furthermore, our recent study with M 1 M 5 receptor knockout mice has shown that the M 3 subtype is expressed predominantly in the submaxillary gland and moderately in the bladder, whereas the M 2 receptor is the major subtype in the bladder. 23 Maruyama et al. suggested that human parotid gland contains predominantly the M 3 subtype based on results of [ 3 H]NMS binding assays with human tissue and membranes of CHO- K1 cell lines expressing the human M 1 M 5 receptor subtypes. 17 Consistent with these results, the predominance of the M 3 receptor in the human parotid gland was demonstrated directly by a radioligand binding assay
4 Imidafenacin in Human Bladder 67 TABLE 2. K i values and Hill coefficients (nh) for in vitro inhibition by imidafenacin and oxybutynin of specific [N-methyl- 3 H]scopolamine methyl chloride ([ 3 H]NMS) binding in homogenates of human detrusor, mucosa and parotid gland Imidafenacin Oxybutynin Tissue K i (nm) nh K i (nm) nh Detrusor 1.80 ± ± ± ± 0.31 Mucosa 2.03 ± ± ± ± 0.17 Parotid gland 0.82 ± 0.17, 0.94 ± ± ± 0.07 The binding of [ 3 H]NMS (1.0 nm) in homogenates of human detrusor, mucosa and parotid gland was measured in the presence of different concentrations of imidafenacin and oxybutynin. The K i and Hill coefficients were estimated. Asterisks show a significant difference from values in human detrusor, **P < Daggers show a significant difference from values with oxybutynin in the same tissue, P < 0.05, P < Each value represents the mean ± SEM for three to seven samples. TABLE 3. Effect of imidafenacin and oxybutynin on K d and B max values for [N-methyl- 3 H]scopolamine methyl chloride ([ 3 H]NMS) binding in homogenates of human detrusor and parotid gland Tissue Drug (pm) (fmol/mg protein) Detrusor Control 281 ± ± 11.5 Imidafenacin (10 nm) 1154 ± 191 (4.11)** 90.4 ± 20.6 Oxybutynin (30 nm) 2494 ± 1209 (8.88)*** 126 ± 43 Parotid gland Control 207 ± ± 48 Imidafenacin (5 nm) 845 ± 168 (4.08)** 127 ± 22 Oxybutynin (30 nm) 667 ± 121 (3.22)** 120 ± 36 The binding of [ 3 H]NMS ( nm) in homogenates of human detrusor and parotid gland was measured in the absence and presence of imidafenacin (5 and 10 nm) and oxybutynin (30 nm). Values in parentheses represent the fold-increase in K d values relative to controls. Asterisks show a significant difference from control values, **P < 0.01, ***P < Each value represents the mean ± SEM for three to four rats. K d B max using N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4- DAMP mustard), an irreversible inactivating agent of the M 3 subtype (Yoshida et al., unpubl. observ., 2010). Since imidafenacin exhibited greater selectivity for the M 3 than M 2 subtype in CHO-K1 cells expressing human muscarinic receptors, 13 the high affinity of this drug for muscarinic receptors in the human parotid gland reflects M 3 -subtype selectivity. In spite of this, imidafenacin was shown to select the bladder over the exocrine gland by in vivo functional and ex vivo muscarinic receptor binding experiments in rats. 14,16 Such in vivo results seem to contradict the M 3 -subtype selectivity in vitro, but the in vivo bladder selectivity may result mainly from the pharmacokinetics of this agent. 16 In conclusion, the present study has revealed that imidafenacin binds muscarinic receptors in the human bladder mucosa and detrusor muscle and parotid gland in a competitive and reversible manner. Imidafenacin may exhibit therapeutic effects on the lower urinary tract symptoms due to an OAB by blocking muscarinic receptors in the urothelium as well as detrusor muscle. Disclosure No conflict of interest. REFERENCES 1. Bulmer P, Abrams P. The overactive bladder. Rev Contemp Pharmacother 2000; 11: Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 2006; 98: Choppin A, Eglen RM. Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle. Br J Pharmacol 2001; 133: Matsui M, Motomura D, Karasawa H et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M 3 subtype. Proc Natl Acad Sci USA 2000; 97: Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005; 144: Tyagi S, Tyagi P, Van-le S, Yoshimura N, Chancellor MB, de Miguel F. Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. JUrol2006; 176: Bschleipfer T, Schukowski K, Weidner W et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci 2007; 80: Kim Y, Yoshimura N, Masuda H, de Miguel F, Chanellor MB. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 2005; 65: Homma Y, Yamaguchi O. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2008; 15: Homma Y, Yamaguchi O. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2009; 16: Homma Y, Yamaguchi T, Yamaguchi O. A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2008;15:
5 68 Masanao Seki et al. 12. Ohno T, Nakade S, Nakayama K et al. Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Br J Clin Pharmacol 2008; 65: Kobayashi F, Yageta Y, Segawa M, Matsuzawa S. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M 3 and M 1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arztl Forsch 2007; 57: Kobayashi F, Yageta Y, Yamazaki T et al. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arztl Forsch 2007; 57: Murakami S, Yoshida M, Iwashita H et al. Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol Int 2003; 71: Yamada S, Seki M, Ogoda M. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder. J Pharmacol Exp Ther 2011; 336: Maruyama S, Oki T, Otsuka A et al. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. JUrol2006; 175: Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: Masuda Y, Kanayama N, Manita S, Ohmori S, Ooie T. Development and validation of bioanalytical methods for imidafenacin (KRP-197/ONO-8025) and its metabolites in human urine by using liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007; 21: Giraldo E, Martos F, Gomez A et al. Characterization of muscarinic receptor subtypes in human tissues. Life Sci 1988; 43: Caufield MP. Muscarinic receptors-characterization, coupling and function. Pharmacol Ther 1993; 58: Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995; 273: Ito Y, Oyunzul L, Seki M, Fujino (Oki) T, Matsui M, Yamada S. Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M 1 -M 5 single subtype knockout mice. Br J Pharmacol 2009; 156:
Shizuo Yamada, Masanao Seki, Masaki Ogoda, Ayako Fukata, Miho Nakamura, and Yoshihiko Ito
0022-3565/11/3362-365 371$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 336, No. 2 Copyright 2011 by The American Society for Pharmacology and Experimental Therapeutics 172288/3658978
More informationJournal of Pharmacological Sciences
Journal of Pharmacological Sciences 128 (2015) 65e70 HOSTED BY Contents lists available at ScienceDirect Journal of Pharmacological Sciences journal homepage: www.elsevier.com/locate/jphs Full paper The
More informationInnovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders
TNe 10 Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders Stuart B. Bauer, MD President, ICCS Department of Urology Children s Hospital Boston Professor of Urology Harvard
More informationEfficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study
LUTS () 3, 36 4 ORIGINAL ARTICLE Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study Naoki WADA, Masaki WATANABE, Masafumi
More informationEfficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder
Urol Sci 21;21(1):38 43 ORIGINAL ARTICLE Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder Yih-Chou Chen, Chia-Yen Chen, Hann-Chorng
More informationAntimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?
Review Article SENSORY ACTIONS OF ANTIMUSCARINICS FINNEY et al. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? STEVEN M. FINNEY, KARL-ERIK
More informationComparison of the Effects by Obybutynin and Tolterodine on Spina Bifida Patients: A Pilot Crossover Study
LUTS (2011) 3, 99 103 ORIGINAL ARTICLE Comparison of the Effects by Obybutynin and Tolterodine on Spina Bifida Patients: A Pilot Crossover Study Akihiro KANEMATSU, 1,2 Kazuyoshi JOHNIN, 2,3 Koji YOSHIMURA,
More informationAnticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
More informationTomomi Oki, Ayako Toma-Okura, and Shizuo Yamada
0022-3565/06/3163-1137 1145$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 316, No. 3 Copyright 2006 by The American Society for Pharmacology and Experimental Therapeutics 94508/3080293
More informationComparative Influence of Imidafenacin and Oxybutynin on Voiding Function in Rats with Functional Urethral Obstruction
306 Original Article Comparative Influence of Imidafenacin and Oxybutynin on Voiding Function in Rats with Functional Urethral Obstruction Authors Affiliation A. Fukata, T. Yamazaki Watarase Research Center,
More informationphenylephrine - phenylephrine
* * Fischer 344 carbachol carbachol M phenylephrine - phenylephrine [ 3 H] quinuclidinyl benzilate (QNB) [ 3 H] QNB QOL quality of life 1 3) 2 Krebs-Henseleit 37 0.1 10 ml organ bath 3 7T-15-240 3 mm NaCl
More informationThe N-Oxide Metabolite Contributes to Bladder Selectivity Resulting from Oral Propiverine: Muscarinic Receptor Binding and Pharmacokinetics
0090-9556/10/3808-1314 1321$20.00 DRUG METABOLISM AND DISPOSITION Vol. 38, No. 8 Copyright 2010 by The American Society for Pharmacology and Experimental Therapeutics 33233/3609163 DMD 38:1314 1321, 2010
More informationComparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa
JPET Fast This Forward. article has not Published been copyedited on and November formatted. The 24, final 2008 version as may DOI:10.1124/jpet.108.145508 differ from this version. JPET #145508 1 Comparison
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationThe role of M 2 -muscarinic receptors in mediating contraction of the pig urinary bladder in vitro
British Journal of Pharmacology (2000) 131, 1482 ± 1488 ã 2000 Macmillan Publishers Ltd All rights reserved 0007 ± 1188/00 $15.00 www.nature.com/bjp The role of M 2 -muscarinic receptors in mediating contraction
More informationJuly 2007 Biol. Pharm. Bull. 30(7) (2007)
July 2007 Biol. Pharm. Bull. 30(7) 1237 1241 (2007) 1237 Prediction of a 1 -Adrenoceptor Occupancy in the Human Prostate from Plasma Concentrations of Silodosin, Tamsulosin and Terazosin to Treat Urinary
More informationClinical guidelines for overactive bladder
International Journal of Urology (2009) 16, 126 142 doi: 10.1111/j.1442-2042.2008.02177.x Guidelines Clinical guidelines for overactive bladder Osamu Yamaguchi, 1 Osamu Nishizawa, 2 Masayuki Takeda, 3
More informationOveractive Bladder; OAB. Aδ silent C. Adenosine triphosphate; ATP SD g n Key words
25-32 2009 SD 200-270g n 28 4 1 2 3 4 PE-50 4-5 0.25 60 C Key words acupuncture stimulation overactive bladder rat bladder irritation C C fiber Received November 17, 2008; Accepted January 9, 2009 I Overactive
More informationURGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
More informationPharmacologically Relevant Receptor Binding Characteristics and 5a-Reductase Inhibitory Activity of Free Fatty Acids Contained in Saw Palmetto Extract
646 Biol. Pharm. Bull. 32(4) 646 650 (2009) Vol. 32, No. 4 Pharmacologically Relevant Receptor Binding Characteristics and 5a-Reductase Inhibitory Activity of Free Fatty Acids Contained in Saw Palmetto
More informationLong-term persistence with mirabegron in a real-world clinical setting
International Journal of Urology (2018) 25, 501--506 doi: 10.1111/iju.13558 Original Article: Clinical Investigation Long-term persistence with in a real-world clinical setting Naoki Wada, Masaki Watanabe,
More informationSupporting Information
Supporting Information Burford et al. 1.173/pnas.1339311 SI Materials and Methods β-arrestin Recruitment Assay. PathHunter human osteosarcoma cells (U2OS) expressing either μ-opioid receptors (U2OS- OPRM1)
More information5 Conservative Treatment for. Pelvic Floor Disorders
5 Conservative Treatment for Pelvic Floor Disorders 23 Pharmacologic Approach to Urinary Incontinence and Voiding Disorders K.-E. Andersson Introduction The main components of the lower urinary tract,
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More informationThe Inhibitory Role of Acetylcholine and Muscarinic Receptors in Bladder Afferent Activity
EUROPEAN UROLOGY 58 (2010) 22 28 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Neuro-urology Editorial by Delphine Behr-Roussel and François A. Giuliano
More informationUrinary nerve growth factor levels could be a biomarker for overactive bladder symptom: a meta-analysis
Urinary nerve growth factor levels could be a biomarker for overactive bladder symptom: a meta-analysis H.C. Qu, S. Yan, X.L. Zhang, X.W. Zhu, Y.L. Liu and P. Wang Department of Urological Surgery, The
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationWhat is on the Horizon in Drug Therapy for OAB?
What is on the Horizon in Drug Therapy for OAB? K-E Andersson, MD, PhD Wake Forest Institute for Regenerative Medicine Wake Forest University School of Medicine Winston Salem, North Carolina Disclosures
More information김준철 가톨릭대학교의과대학비뇨기과학교실
비뇨기계자율신경병증의치료 김준철 가톨릭대학교의과대학비뇨기과학교실 Introduction Urologic complications have increasingly become a concern in those affected by DM Genitourinary problems are included among these complications, related
More informationAnticholinergic activity in the serum of patients receiving maintenance disopyramide therapy
Br. J. clin. Pharmac. (1984), 17,325-329 Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy E. IISALO & L. AALTONEN Department of Pharmacology, University of Turku,
More informationDRUG FORECAST. Select Conditions of the Lower Urinary Tract
Transdermal Oxybutynin: Novel Drug Delivery for Overactive Bladder Vitalina Rozenfeld, PharmD, BCPS, Stanley Zaslau, MD, Kathleen New Geissel, PharmD, David Lucas, PhD, and Lili Babazadeh, PharmD INTRODUCTION
More informationOriginal Article. J Fac Med Baghdad 119. Nibbras I. AL-Hamdani* Ali W. Zeki*** Introduction:
Original Article The Efficacy of Solifenacin Added to Α-Adrenergic Antagonists in the Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience) Nibbras
More informationAQP0 Low Lens eyeball Cataract
Topics Kampo Medicine Water-Metabolism Regulatory Action of Chinese Herbal Medicine Yoichiro Isohama Field of Drug Activities, Bioscience Research Div. Graduate School of Kumamoto University 1. Introduction
More informationLa vescica iperattiva: dalla diagnosi ai nuovi approcci terapeutici
La Prostata nel Mirino Napoli, 1 dicembre 2016 La vescica iperattiva: dalla diagnosi ai nuovi approcci terapeutici Giorgio Annoni Cattedra e Scuola di Specializzazione in Geriatria Università degli Studi
More information3/20/10. Prevalence of OAB Men: 16.0% Women: 16.9% Prevalence of OAB with incontinence (OAB wet) Men: 2.6% Women: 9.3% Dry. Population (millions) Wet
1 Prevalence of OAB Men: 16.0% Women: 16.9% Stewart WF, et al. World J Urol. 2003;20:327-336. Prevalence of OAB with incontinence (OAB wet) Men: 2.6% Women: 9.3% Stewart WF, et al. World J Urol. 2003;20:327-336.
More informationUrinary Incontinence in Women: Never an Acceptable Consequence of Aging
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging Catherine A. Matthews, MD Associate Professor Chief, Urogynecology and Pelvic Reconstructive Surgery University of North Carolina,
More informationSUMMARY MATERIALS AND METHODS INTRODUCTION
Med. J. Malaysia VoI. 38 No. 2 June 1983 OESTROGEN RECEPTOR STATUS OF BREAST TUMOUR BIOPSIES IN MALAYSIAN PATIENTS SHAHARUDDIN AZIZ SUMMARY This communication describes the quantitative and qualitative
More informationComparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder
European Urology European Urology 48 (2005) 110 115 Female UrologyöIncontinence Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder Martin
More informationSolifenacin significantly improves all symptoms of overactive bladder syndrome
REVIEW doi: 10.1111/j.1742-1241.2006.01067.x Solifenacin significantly improves all symptoms of overactive bladder syndrome C. R. CHAPPLE, 1 L. CARDOZO, 2 W. D. STEERS, 3 F. E. GOVIER 4 1 Department of
More informationOveractive Bladder (OAB) Step Therapy Program Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:
Overactive Bladder (OAB) Step Therapy Program Policy Number: 5.01.556 Origination: 07/2013 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for brand name Overactive Bladder
More informationRESEARCH PAPER AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladderbph_
British Journal of Pharmacology (21), 16, 1119 1127 21 Ranbaxy Laboratories Ltd. Journal compilation 21 The British Pharmacological Society All rights reserved 7-1188/1 www.brjpharmacol.org RESEARCH PAPER
More information(2) Assistant Professor of Pathology
The Association between (Serum prostatic specific antigen and Dihydrotestosterone) and Efficacy of Solifenacin Therapy for Benign prostatic hypertrophy Patient in Salahalddin (1) Mohammed Mohsin Abdul-Aziz,
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationOveractive Bladder (OAB) Step Therapy Program
Overactive Bladder (OAB) Step Therapy Program Policy Number: 5.01.556 Last Review: 11/2018 Origination: 7/2013 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationSignal transduction underlying the control of urinary bladder smooth muscle tone Puspitoayu, E.
UvA-DARE (Digital Academic Repository) Signal transduction underlying the control of urinary bladder smooth muscle tone Puspitoayu, E. Link to publication Citation for published version (APA): Puspitoayu,
More informationYuan et al., Afr J Tradit Complement Altern Med. (2014) 11(4):
IZALPININ FROM FRUITS OF ALPINIA OXYPHYLLA WITH ANTAGONISTIC ACTIVITY AGAINST THE RAT BLADDER CONTRACTILITY 120 Yuan Yuan 1,5#, Yin-Feng Tan 2,3,4#, Peng Xu 2,3,4, Hailong Li 2,3,4, Yong-Hui Li 2,3,4,
More informationAutonomic Nervous System (ANS):
Autonomic Nervous System (ANS): ANS is the major involuntary, unconscious, automatic portion of the nervous system. involuntary voluntary The motor (efferent)portion of the ANS is the major pathway for
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationVoiding Dysfunction. Yao-Chi Chuang,* Jonathan H. Kaufmann, David D. Chancellor, Michael B. Chancellor and Hann-Chorng Kuo,k
Voiding Dysfunction Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial Yao-Chi Chuang,* Jonathan
More informationPHRM20001: Pharmacology - How Drugs Work!
PHRM20001: Pharmacology - How Drugs Work Drug: a chemical that affects physiological function in a specific way. Endogenous substances: hormones, neurotransmitters, antibodies, genes. Exogenous substances:
More informationDrugs for the overactive bladder: are there differences in persistence and compliance?
Editorial Drugs for the overactive bladder: are there differences in persistence and compliance? Karl-Erik Andersson 1,2 1 Institute for Regenerative Medicine, Wake Forest University School of Medicine,
More informationBotulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationSafety and Tolerability Profiles of Anticholinergic Agents Used for the Treatment of Overactive Bladder
REVIEW ARTICLE Drug Saf 2011; 34 (9): 733-754 0114-5916/11/0009-0733/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Safety and Tolerability Profiles of Anticholinergic Agents Used for the
More informationNaoki Wada, Seiji Matsumoto, Masafumi Kita, Kazumi Hashizume and Hidehiro Kakizaki
bs_bs_banner International Journal of Urology (1) 1, 15 1 doi: 1.1111/iju.157 Original Article: Clinical Investigation Decreased urinary nerve growth factor reflects prostatic volume reduction and relief
More informationC Salcedo, S Davalillo, J Cabellos, C Lagunas, D Balsa*, S Pérez-del-Pulgar, M Ballarín and AG Fernández
British Journal of Pharmacology (29), 156, 87 817 29 The Authors Journal compilation 29 The British Pharmacological Society All rights reserved 7-1188/9 www.brjpharmacol.org RESEARCH PAPER In vivo and
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationSELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
More informationPossible Effect of Carbamazepine A Sodium Channel Blocker on Urinary Bladder Dysfunction in Type-1 Diabetic Patients
Med. J. Cairo Univ., Vol. 84, No. 1, March: 85-90, 2016 www.medicaljournalofcairouniversity.net Possible Effect of Carbamazepine A Sodium Channel Blocker on Urinary Bladder Dysfunction in Type-1 Diabetic
More informationMuscarinic receptor antagonists for overactive bladder
Great drug classes ANTIMUSCARINIC DRUGS FOR OAB From time to time we publish a full review of drugs that are available for the treatment of common conditions. In this issue, the review is written by two
More informationPrimary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
More informationSolifenacin: a new drug for the treatment of overactive bladder and detrusor overactivity
DRUG PROFILE Solifenacin: a new drug for the treatment of overactive bladder and detrusor overactivity Jean-Jacques Wyndaele University Hospital Antwerp, Department of Urology, 10 Wilrijkstraat, B 2650
More informationOD Tablets 0.1 mg. URITOS OD Tablets 0.1 mg
Kyorin Pharmaceutical Co., Ltd. 1 Revised: June 2017(12th version) Standard Commodity Classification No. of Japan 87259 Storage Tablets 0.1 mg: stored at room temperature OD Tablets 0.1 mg: stored in a
More informationBiology of the Salivary Glands 513 (KEY) MID-TERM Examination May 23, 2001
Multiple Choice Biology of the Salivary Glands 513 (KEY) MID-TERM Examination May 23, 2001 1. Pilocarpine inhibits secretion more than propranolol because: a. It is a cholinergic agonist and therefore
More informationNew Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationDr Jonathan Evans Paediatric Nephrologist
How do I manage a patient with intractable daytime wetting: Dr Jonathan Evans Paediatric Nephrologist Of 107 children aged 11-12 with day-wetting 91 (85%) were dry at 15-16 yr Swithinbank et al BJU 1998
More informationPosterior Tibial Nerve Stimulation
Posterior Tibial Nerve Stimulation Policy Number: Original Effective Date: MM.02.025 01/01/2015 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2015 Section: Medicine Place(s)
More informationOriginal Article. Annals of Rehabilitation Medicine INTRODUCTION
Original Article Ann Rehabil Med 2014;38(3):342-346 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2014.38.3.342 Annals of Rehabilitation Medicine Phasic Changes in Bladder Compliance
More informationTentu Nageswara Rao et al. / Int. Res J Pharm. App Sci., 2012; 2(4): 35-40
International Research Journal of Pharmaceutical and Applied Sciences Available online at www.irjpas.com Int. Res J Pharm. App Sci., 2012; 2(4):35-40 Research Article Estimation of Fesoterodine fumarate
More informationVoiding Dysfunction. Jae Hyun Bae, Sun Ouck Kim 1, Eun Sang Yoo 2, Kyung Hyun Moon 3, Yoon Soo Kyung 4, Hyung Jee Kim 4
www.kjurology.org DOI:10.4111/kju.2011.52.4.274 Voiding Dysfunction Efficacy and Safety of Low-Dose Propiverine in Patients with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia with Storage Symptoms:
More informationEfficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study Yoshihisa Matsukawa,* Momokazu Gotoh, Tomonori Komatsu, Yasuhito Funahashi, Naoto Sassa and Ryohei Hattori
More informationDrug Receptor Interactions and Pharmacodynamics
Drug Receptor Interactions and Pharmacodynamics Dr. Raz Mohammed MSc Pharmacology School of Pharmacy 22.10.2017 Lec 6 Pharmacodynamics definition Pharmacodynamics describes the actions of a drug on the
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationMr. GIT KAH ANN. Pakar Klinikal Urologi Hospital Kuala Lumpur.
Mr. GIT KAH ANN Pakar Klinikal Urologi Hospital Kuala Lumpur drgitka@yahoo.com 25 Jan 2007 HIGHLIGHTS Introduction ICS Definition Making a Diagnosis Voiding Chart Investigation Urodynamics Ancillary Investigations
More informationThis chapter deals with the evaluation of alpha amylase inhibitory
This chapter deals with the evaluation of alpha amylase inhibitory activity of different extracts isolated from leaves of Aloe vera L. and leaves of Azadiracta indica A Juss. collected from Bharatpur and
More informationVibegron 50 mg n = 118. Completed n = 102. Safety analysis set (SAF) Full analysis set (FAS)
International Journal of Urology (218) 25, 668--675 doi: 1.1111/iju.13596 Original Article: Clinical Investigation Long-term safety and efficacy of the novel b 3 -adrenoreceptor agonist vibegron in Japanese
More informationTreatment of OAB in postmenopause. Držislav Kalafatić Department Obstetrics and Gynecology School of Medicine, University of Zagreb
Treatment of OAB in postmenopause Držislav Kalafatić Department Obstetrics and Gynecology School of Medicine, University of Zagreb Spectrum of overactive bladder Urinary urgency usually accompanied by
More informationIs There a Best Drug for Overactive Bladder in a Patient with Dementia?
Is There a Best Drug for Overactive Bladder in a Patient with Dementia? Todd Semla, MS, Pharm.D., BCPS, FCCP, AGSF National PBM Clinical Pharmacy Program Manager Mental Health & Geriatrics U.S. Department
More informationShort Communication. Abstract. Introduction
Short Communication JPP, 6: 76 7 The Authors JPP Royal Pharmaceutical Society Received November 8, Accepted February, DOI./j.-758..76.x ISSN -57 Relationship between lipophilicity and absorption from the
More informationDiagnosis and Treatment of Overactive Bladder
Diagnosis and Treatment of Overactive Bladder Case study: Mr. Lin I I have started to rush out of meetings to go to the toilet I I need to void every one hour I I used to be quite active. This is becoming
More informationIntravesical Drug Delivery for Dysfunctional Bladder
Intravesical Drug Delivery for Dysfunctional Bladder Yao-Chi Chuang Professor and Chief, Division of Urology, Kaohsiung Chang Gung Memorial Hospital, Taiwan 成長於台南 建興國中 台南一中 2 Yao-Chi Chuang In connection
More informationRetrospective Analysis of Efficacy and Tolerability of Tolterodine in Children with Overactive Bladder
European Urology European Urology 45 (2004) 240 244 Retrospective Analysis of Efficacy and Tolerability of Tolterodine in Children with Overactive Bladder A. Raes a,, P. Hoebeke b, I. Segaert a, E. Van
More informationComparative Study of Solifenecin Alone Versus Solifenecin with Duloxetine in Patients of Overactive Bladder
International Journal of Scientific and Research Publications, Volume 3, Issue 1, January 2013 1 Comparative Study of Solifenecin Alone Versus Solifenecin with Duloxetine in Patients of Overactive Bladder
More informationThe International Continence Society
REPORTS Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in Adults Richard G. Roberts, MD, JD; Alan D. Garely, MD; and Tamara Bavendam, MD Abstract This article evaluates
More informationPHARMACODYNAMICS II. The total number of receptors, [R T ] = [R] + [AR] + [BR] (A = agonist, B = antagonist, R = receptors) = T. Antagonist present
Pharmacology Semester 1 page 1 of 5 PHARMACODYNAMICS II Antagonists Are structurally similar to the binding site of a receptor and thus show affinity towards the receptor. However, they have zero intrinsic
More informationAbstract. matl0n relatlve to the
Jpn. J. Clin. Oncol. 1980, 10 (1) 61 ~ 68 Re-Evaluation of Clinical Parameters in Relation to Estrogen Receptor Assay in Predicting Response to Major Endocrine Ablation Therapy in Patients with Advanced
More informationDepartment of Urology, Yantai Affiliated Hospital of Binzhou Medicine University, Yantai, China. 3
Official Journal of Korean Continence Society / Korean Society of Urological Research / The Korean Children s Continence and Enuresis Society / The Korean Association of Urogenital Tract Infection and
More informationModule Objectives: Why to study Organic Pharmaceutical Chemistry? 24-Oct-17
1 2 Useful Info: Students are encouraged to visit the faculty website: http://pharmacy.uokerbala.edu.iq/ And most importantly the e-learning website: http://elearning.uokerbala.edu.iq Nevertheless, feel
More informationAutonomic Nervous System
Autonomic Nervous System Touqeer Ahmed PhD 3 rd March, 2017 Atta-ur-Rahman School of Applied Biosciences National University of Sciences and Technology Nervous System Divisions The peripheral nervous system
More informationHiroshi Yagi, M.D., Gaku Arai, M.D., Shigehiro Soh, M.D., Hiroshi Okada, M.D.
Dokkyo Journal of Medical Sciences (1)(2017) (1):9 once-daily 15,2017 oxybutynin patch for overactive bladder in patients not tolerating oral antimuscarinic drugs 9 Efficacy and Safety of Once-daily Oxybutynin
More informationNeural Control of Lower Urinary Tract Function. William C. de Groat University of Pittsburgh Medical School
Neural Control of Lower Urinary Tract Function William C. de Groat University of Pittsburgh Medical School Disclosures Current funding: NIH Grants, DK093424, DK-091253, DK-094905, DK-090006. Other financial
More informationAutonomic Pharmacology: Cholinergic agonists
Autonomic Pharmacology: Cholinergic agonists Öner Süzer www.onersuzer.com osuzer@istanbul.edu.tr Last update: 23.01.2013 1 Acetylcholine Acetylcholine (ACh), the naturally occurring neurotransmitter for
More informationA Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the b3-adrenoceptor Agonist Solabegron for Overactive Bladder
EUROPEAN UROLOGY 62 (2012) 834 840 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Voiding Dysfunction Editorial by Christopher R. Chapple on pp. 841 842
More informationLong-Term Safety, Tolerability and Ef cacy of Extended-Release Tolterodine in the Treatment of Overactive Bladder
European Urology European Urology 41 (2002) 588±595 Long-Term Safety, Tolerability and Ef cacy of Extended-Release Tolterodine in the Treatment of Overactive Bladder K. Kreder a,*, C. Mayne b, U. Jonas
More informationINTRODUCTION TO GASTROINTESTINAL FUNCTIONS
1 INTRODUCTION TO GASTROINTESTINAL FUNCTIONS 2 Learning outcomes List two main components that make up the digestive system Describe the 6 essential functions of the GIT List factors (neurological, hormonal
More informationPharmacologyonline 2: (2008) Newsletter Deepraj and Nandakumar
INVESTIGATION OF ISOLATED GOAT ILEUM PREPARATION FOR THE SUITABILITY AS A TEACHING AID FOR UNDER GRADUATE AND POST GRADUATE PRACTICALS Deepraj Paul, K.Nandakumar DEPARTMENT OF PHARMACOLOGY, P.E.S COLLEGE
More informationOveractive bladder syndrome (OAB)
Service: Urology Overactive bladder syndrome (OAB) Exceptional healthcare, personally delivered What is OAB? An overactive bladder or OAB is where a person regularly gets a sudden and compelling need or
More informationEffect of ageing on ƒ 1A-adrenoceptor mechanisms in rabbit. Issei TAKAYANAGI, Mann MORIYA and Katsuo KOIKE
J. Smooth Muscle Res. 28: 63-68, 1992. Effect of ageing on ƒ 1A-adrenoceptor mechanisms in rabbit isolated bronchial preparations Issei TAKAYANAGI, Mann MORIYA and Katsuo KOIKE Department of Chemical Pharmacology,
More informationDMD Fast Forward. Published on June 13, 2007 as DOI: /dmd
DMD Fast This article Forward. has not been Published copyedited on and June formatted. 13, The 2007 final version as doi:10.1124/dmd.107.016030 may differ from this version. Absorption, Metabolism and
More informationThe Management of Overactive Bladder Syndrome with Antimuscarinic Drugs
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs Author Version Date Consultation Date of Ratification By JPG Shaista Hussain Joint Formulary Pharmacist V2 16.09.2014 Homerton University
More informationPHARMACOLOGY-1 PHL-313. Ali Alhoshani Office: 2B 84
PHARMACOLOGY-1 PHL-313 Ali Alhoshani ahoshani@ksu.edu.sa http://fac.ksu.edu.sa/ahoshani Office: 2B 84 General rules Reference: General rules Email [PHL313-1 st Semester 38-39] Student ID- Question Example
More information